Seo Jong-Wook, Lee Dong-Yun, Yoon Byung-Koo, Choi DooSeok
Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Eur J Obstet Gynecol Reprod Biol. 2017 Jan;208:81-85. doi: 10.1016/j.ejogrb.2016.11.015. Epub 2016 Nov 16.
As endometrioma frequently recurs after conservative surgery, long-term postoperative medical treatment for the prevention of recurrence is necessary. However, it has not been elucidated whether long-term postoperative medical treatment is crucial to all patients until menopause. Thereupon, this study was conducted to evaluate the age-related recurrence patterns after conservative surgery for endometrioma.
A retrospective cohort study was performed on a total of 420 reproductive-aged women who underwent conservative surgery for endometrioma between January 2000 and December 2010. Ultrasonography was used during the follow-up period to detect endometrioma recurrence. Patients were classified into two groups according to the use of postoperative medications. The first group was observation only, while the second received gonadotropin releasing hormone agonists followed by cyclic oral contraceptives. The cumulative recurrence rate of endometrioma was compared according to the age at surgery (20-29 years, 30-39 years, 40-45 years) within each group. Subgroup analysis was performed according to the age between the two groups.
The median follow-up duration after surgery was 29.0 months (range 6-159 months) for all patients. After adjusting for parity, size and bilaterality of cyst, and stage with American Society for Reproductive Medicine classification of endometriosis which was statistically different, within the group of no treatment, the cumulative recurrence rate in 40-45 years (10.2%) was significantly lower compared with those in 20-29 years (43.3%; hazard ratio (HR)=0.04; 95% confidence interval (CI)=0.01-0.52) and 30-39 years (22.5%; HR=0.19; 95% CI=0.04-0.92). However, there were no differences within the group of postoperative medical treatment. When we compared between the two groups, the cumulative recurrence rate was significantly different in 20-29 years (8.1 vs 43.3%; p<0.001) and 30-39 years (5.4 vs 22.5%; p=0.007), but there was no difference in 40-45 years (4.5 vs 10.2%; p=0.901).
Our preliminary results demonstrate that the risk of endometrioma recurrence decreases with age. After the age of forty, the recurrence rate does not differ according to the use of postoperative medication. Based on our results, postoperative medical treatment may be individualized according to the patient's age at the time of surgery. Further studies are needed to identify patients who may benefit from postoperative medication.
由于子宫内膜异位囊肿在保守性手术后常复发,术后长期药物治疗以预防复发是必要的。然而,长期术后药物治疗对所有患者直至绝经是否至关重要尚未阐明。因此,本研究旨在评估子宫内膜异位囊肿保守性手术后与年龄相关的复发模式。
对2000年1月至2010年12月间共420例行子宫内膜异位囊肿保守性手术的育龄妇女进行回顾性队列研究。随访期间采用超声检查检测子宫内膜异位囊肿复发情况。根据术后用药情况将患者分为两组。第一组仅观察,第二组接受促性腺激素释放激素激动剂治疗,随后服用周期性口服避孕药。在每组中,根据手术时年龄(20 - 29岁、30 - 39岁、40 - 45岁)比较子宫内膜异位囊肿的累积复发率。对两组间的年龄进行亚组分析。
所有患者术后中位随访时间为29.0个月(范围6 - 159个月)。在调整了产次、囊肿大小和双侧性以及采用美国生殖医学学会子宫内膜异位症分类法进行的分期(这些因素在统计学上有差异)后,在未治疗组中,40 - 45岁组的累积复发率(10.2%)显著低于20 - 29岁组(43.3%;风险比(HR)=0.04;95%置信区间(CI)=0.01 - 0.52)和30 - 39岁组(22.5%;HR = 0.19;95% CI = 0.04 - 0.92)。然而,术后药物治疗组内无差异。当我们比较两组时,20 - 29岁组(8.1%对43.3%;p < 0.001)和30 - 39岁组(5.4%对22.5%;p = 0.007)的累积复发率有显著差异,但40 - 45岁组无差异(4.5%对10.2%;p = 0.901)。
我们的初步结果表明,子宫内膜异位囊肿复发风险随年龄降低。四十岁以后,复发率不因术后用药情况而异。根据我们的结果,术后药物治疗可根据患者手术时的年龄个体化。需要进一步研究以确定可能从术后用药中获益的患者。